BioCardia Reports Q1 2026 Earnings and Regulatory Progress

BioCardia (BCDA) announced positive developments in its CardiAMP Cell Therapy for ischemic heart failure, including FDA Breakthrough Designation and regulatory progress in Japan. The company also highlighted clinical efficacy results from the CardiAMP Heart Failure trial and ongoing trials.

By Motley Fool Transcribing · Motley Fool · May 18, 2026, 12:40 UTC

BioCardia Reports Q1 2026 Earnings and Regulatory Progress

Topics: biotech cardiovascular_treatment clinical_trials

Read the full article at Motley Fool

More World news

Micron Shares Decline Following Resignation of Nvidia CEO Jensen Huang Motley Fool · November 12, 2026, 15:44 UTC
Wirex Launches Navoka AI Agent with Dedicated Bank Account and Card PR Newswire · November 12, 2026, 15:44 UTC
Mobility Global Shares Rise 12% Following Q3 Earnings Beat and Improved EBITDA Outlook Seeking Alpha · November 12, 2026, 15:44 UTC
Lucid Diagnostics Reports Q3 2026 Results Amid Transition to Medicare Reimbursement Motley Fool · November 12, 2026, 15:39 UTC
National Vision Reports Q3 2026 Revenue Growth Driven by Higher Average Ticket Motley Fool · November 12, 2026, 15:40 UTC
Okeanis Eco Tankers Reports Record Q3 2026 Results Driven by High Freight Rates Motley Fool · November 12, 2026, 15:41 UTC
Nvidia Shares Plunge Following Resignation of CEO Jensen Huang Motley Fool · November 12, 2026, 15:35 UTC
Jensen Huang Resigns as Nvidia CEO; Colette Kress Appointed Interim CEO TechCrunch · November 12, 2026, 15:37 UTC
Merck KGaA Raises 2026 Outlook Amid Pending Bio-Techne Acquisition Seeking Alpha · November 12, 2026, 15:31 UTC
Chinese AI Firms Seek Alternative Access to Nvidia Chips Amid Potential US Export Restrictions Seeking Alpha · November 12, 2026, 15:32 UTC